Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase I/II Study of R340 (Capecitabine), L-OHP (Oxaliplatin) and R435 (Bevacizumab) in Advanced and/or Metastatic Colorectal Cancer

NCT00345761 is registered in ClinicalTrials.gov with Chugai Pharmaceutical as lead sponsor.

NCT NCT00345761
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00345761 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase I/II Study of R340 (Capecitabine), L-OHP (Oxaliplatin) and R435 (Bevacizumab) in Advanced and/or Metastatic Colorectal Cancer
Lead sponsor
Chugai Pharmaceutical
Phase
Phase 1/2
Overall status
Completed
Start date
February 28, 2006
Completion date
July 31, 2010
Enrollment
64 (actual)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

colorectal cancer